Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
CRANBURY, N.J., March 31, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for …
Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe Read More »